Skip to main content

A Pharmacodynamic Model for Thiazinamium in Asthmatic Patients

  • Chapter
Pharmacokinetics

Abstract

Thiazinamium is a quaternary ammonium phenothiazine and clinically useful bronchodilator. Its mechanism of action is thought to be mediated by a combination of antimuscarinic and antihistaminic properties and its efficacy in the treatment of bronchoconstriction appears to be superior to epinephrine and aminophylline (1). Although it has been in clinical use for over 25 years, little is known about its pharmacokinetics and pharmacodynamics in humans (2,3). A prominent side effect of thiazinamium use is an increase in heart rate presumed to be due to vagal blockade. We have investigated the relationship between plasma thiazinamium concentration and the change in airways obstruction and heart rate to help provide rational dosing guidelines for the treatment of bronchoconstriction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I.H. Booy-Noord, N.G.M. Orie, H.J. Ten Cate, S. Sloots and D. Bolt, The influence of various drugs on the vital capacity of asthmatics, Int. Arch. Allergy 10: 321–341 (1957).

    Article  PubMed  CAS  Google Scholar 

  2. J.H.G. Jonkman, J. Wijsbeek, S. Hollenbeek Brouwer-de Boer, R.A. de Zeeuw, L.E. van Bork and N.G.M. Orie, Determination of low concentrations of the quaternary ammonium compound thiazinamium methylsulphate in plasma and urine, J. Pharm. Pharmacol. 27: 849–854 (1975).

    Article  PubMed  CAS  Google Scholar 

  3. L.E. Van Bork, J.H.G. Jonkman, R.A. de Zeeuw, N.G.M. Orie, R. Peset and K. de Vries, Diagnostisch en therapeutisch gebruik van thiazinamium (Multergan), Ned. T. Geneesk. 121: 1196–1202 (1977).

    PubMed  Google Scholar 

  4. N.H.G. Holford, MKMODEL - A mathematical modelling tool for the PROPHET system, “PROPHET Public Procedures Manual,” H.M. Perry, ed., Bolt, Beranek and Newman, Boston (1982) 4:125–129.

    Google Scholar 

  5. W.F. Raub, The PROPHET system and resource sharing, Fed. Proc. 33: 2390 (1976).

    Google Scholar 

  6. N.H.G. Holford and L.B. Sheiner, Understanding the dose-effect relationship, Clin. Pharmacokin. 6: 429–453 (1981).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Plenum Press, New York

About this chapter

Cite this chapter

Holford, N.H.G., Clements, P., Collier, P., Orie, N.G.M., van Bork, L.E., Jonkman, J.H.G. (1984). A Pharmacodynamic Model for Thiazinamium in Asthmatic Patients. In: Benet, L.Z., Levy, G., Ferraiolo, B.L. (eds) Pharmacokinetics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2799-8_56

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2799-8_56

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9725-3

  • Online ISBN: 978-1-4613-2799-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics